Pfizer 's (nyse: PFE - news - people ) Bextra, which increased the risk of heart attack and stroke in patients undergoing open heart surgery, and Arcoxia, Merck's (nyse: MRK - news - people ) still experimental follow-up to Vioxx, are the focus of a great deal of concern.

FORBES: Can Vioxx Rivals Take The Pressure?

Although full data is not available, two studies using the pill and an injectible version of the same drug as painkillers for patients undergoing open-heart surgery have now shown it raises the risk of new heart attacks.

FORBES: Can Vioxx Rivals Take The Pressure?